$CBLL News

Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026

Is CeriBell’s (CBLL) Expanded EEG Software Deepening Its Moat in Critical Care Monitoring?

CeriBell (CBLL) After FDA Clearance Looks Pricey Despite Stronger Adoption Hopes

TD Cowen Maintains Buy on CeriBell, Raises Price Target to $33

CeriBell: FDA Clearances And Delirium Expansion Could Create A New Growth Driver

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

BTIG Reiterates Buy on CeriBell, Maintains $30 Price Target

BTIG Maintains Buy on CeriBell, Raises Price Target to $30

CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push

Canaccord Genuity Maintains Buy on CeriBell, Raises Price Target to $26

BTIG Reiterates Buy on CeriBell, Maintains $28 Price Target

CeriBell, Inc. (CBLL) Q2 2026 Earnings Call Transcript

CeriBell Inc (CBLL) (Q2 2026) Earnings Call Highlights: Revenue Accelerates 33% on Record ...

CeriBell, Inc. Q2 2026 Earnings Call Summary

CeriBell (CBLL) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings

CeriBell Q2 Earnings Call Highlights

CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates

Ceribell Reports Second Quarter 2026 Financial Results

CeriBell Raises FY2026 Sales Guidance from $112.000M-$116.000M to $114.000M-$117.000M vs $113.979M Est